Amgen is set to launch its Eylea biosimilar, Pavblu, after a court ruling lifted a temporary injunction that had blocked its introduction. Despite Regeneron's claims of patent infringement and plans to continue legal battles, analysts suggest Amgen's move may be a tactic to prompt a settlement. The legal dispute intensified after a district court denied Regeneron's request for a preliminary injunction, allowing Amgen to proceed with its launch "at risk."
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
